IGF2BP1 Stabilization of THBS1: A New Mechanistic Axis in Pulmonary Fibrosis

Study Background and Research Question

Pulmonary fibrosis (PF) is a progressive, often fatal, interstitial lung disease marked by excessive extracellular matrix deposition and fibroblast accumulation, ultimately leading to compromised respiratory function. While the clinical and histological hallmarks of PF are established, the precise molecular drivers—particularly those linking macrophage activation states, metabolic reprogramming, and fibrosis—remain insufficiently understood. Recent research has begun to implicate epigenetic mechanisms, notably N6-methyladenosine (m6A) RNA modification, in regulating these pathways. However, the specific contribution of m6A reader proteins, such as insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1), to macrophage-driven fibrosis has not been fully elucidated. The study by Hu et al. (2025) addresses this knowledge gap by investigating whether IGF2BP1 modulates the progression of pulmonary fibrosis via stabilization of thrombospondin-1 (THBS1) mRNA and subsequent effects on macrophage metabolism and phenotype.

Key Innovation from the Reference Study

The central innovation of the study is the identification of a novel IGF2BP1/THBS1/TLR4 regulatory axis that orchestrates both metabolic and functional reprogramming of macrophages during pulmonary fibrosis. Specifically, the authors demonstrate that IGF2BP1, acting as an m6A reader, binds to and stabilizes THBS1 mRNA in an m6A-dependent manner. This post-transcriptional regulation enhances THBS1 expression, which in turn interacts with toll-like receptor 4 (TLR4) to potentiate macrophage M2 polarization and glycolytic activation. This pathway links epigenetic modification to metabolic and phenotypic shifts in macrophages, which are already established contributors to fibrotic tissue remodeling. The study thus unifies previously disparate observations regarding macrophage activation, glycolytic reprogramming, and fibrosis progression, providing a mechanistic basis for targeting these processes in PF (reference).

Methods and Experimental Design Insights

To dissect the role of IGF2BP1 in pulmonary fibrosis, the researchers employed a multifaceted experimental approach in both in vivo and in vitro systems:

• Animal Model: Bleomycin-induced pulmonary fibrosis in mice was used as the primary in vivo model, allowing for histopathological and molecular assessment of fibrosis severity.
• Gene Manipulation: IGF2BP1 knockdown was achieved using lentiviral vectors, and the effect of THBS1 overexpression or knockdown was further evaluated in the context of IGF2BP1 loss.
• Cellular Analyses: Flow cytometry and immunofluorescence were used to quantify macrophage subpopulations (M1 vs. M2), while primary embryonic lung fibroblasts and macrophage cell lines provided mechanistic insights.
• Metabolic Assays: Glycolytic flux was assessed by measuring glucose uptake, lactate production, ATP levels, and the expression of key glycolytic enzymes (HK2, LDHA, PKM2).
• RNA Stability and Interaction: RNA immunoprecipitation and mRNA decay assays established the direct binding and stabilization of THBS1 mRNA by IGF2BP1 in an m6A-dependent fashion. Co-immunoprecipitation and proximity ligation assays demonstrated physical interaction between THBS1 and TLR4.

This comprehensive methodology enabled the authors to trace the causal chain from IGF2BP1 activity to functional and metabolic changes in macrophage populations and ultimately to fibrotic outcomes.

Protocol Parameters

• Bleomycin Administration: Mice were treated with intratracheal bleomycin (1.5–2 mg/kg) to induce lung fibrosis, with endpoints at days 7–21 for tissue analysis.
• IGF2BP1 Knockdown: Lentiviral shRNA vectors were administered to achieve macrophage-specific knockdown prior to or concurrent with fibrosis induction.
• THBS1 Overexpression/Knockdown: Plasmid or siRNA transfection in vitro (e.g., in RAW264.7 macrophages) and in vivo delivery as appropriate for rescue experiments.
• Macrophage Polarization Assays: Flow cytometry for CD68+/CD163+ (M2) and CD68+/CD86+ (M1) markers; qPCR and ELISA for polarization-associated genes such as Arg1, CCL18, Ym1, and IL-6.
• Metabolic Flux Measurement: Glucose and lactate quantification in conditioned media, ATP assay kits, and western blot/qPCR for glycolytic enzymes.

Core Findings and Why They Matter

The study establishes several mechanistically linked findings:

• IGF2BP1 Overexpression in PF: IGF2BP1 is significantly upregulated in the macrophages of bleomycin-induced fibrotic mouse lungs.
• Fibrosis Attenuation by IGF2BP1 Knockdown: Reducing IGF2BP1 levels markedly dampens PF pathology, including decreased inflammatory infiltration, fibroblast accumulation, Ashcroft scores, and hydroxyproline content.
• Suppression of Fibrotic and Inflammatory Markers: Knockdown lowers expression of TGF-β1, α-SMA, collagen I/III, and a suite of M2 and inflammatory cytokines, while reducing the proportion of CD163+ M2 macrophages.
• Direct m6A-Dependent Stabilization of THBS1: IGF2BP1 binds to m6A-modified THBS1 mRNA, increasing its stability and abundance.
• THBS1 as a Downstream Effector: Forced THBS1 expression rescues the inhibitory effects of IGF2BP1 knockdown on M2 polarization and glycolysis, restoring key metabolic enzyme expression, glucose/lactate flux, and ATP production.
• TLR4 Mediation: THBS1 physically interacts with TLR4, and TLR4 overexpression reverses the suppression of M2 polarization and glycolytic reprogramming caused by THBS1 loss.

Together, these results demonstrate that the IGF2BP1/THBS1/TLR4 axis promotes macrophage metabolic reprogramming (enhanced glycolysis) and M2 phenotype skewing, both of which are essential for fibrosis progression. This mechanistic insight suggests that modulating this axis could yield therapeutic benefit by disrupting the pathological activation of macrophages in PF (reference).

Comparison with Existing Internal Articles

Internal literature, such as the article "IGF2BP1 Drives Macrophage Glycolytic Reprogramming in Pulmonary Fibrosis", aligns with the reference study in highlighting the centrality of IGF2BP1 in orchestrating macrophage metabolism and polarization. Both sources emphasize the role of m6A-dependent stabilization of THBS1 and the subsequent activation of TLR4 signaling as key steps in the progression of fibrosis. Furthermore, guidance from articles like "Recombinant Mouse Macrophage Colony Stimulating Factor: A..." and "Applied Uses of Recombinant Mouse M-CSF in Macrophage Assays" provide practical insights on leveraging macrophage growth factors to support the differentiation and functional assays necessary for such mechanistic studies. Notably, these resources reinforce the importance of reproducible macrophage activation for investigating the molecular underpinnings of fibrosis, as established by the reference paper.

Limitations and Transferability

While the study provides a robust mechanistic framework, several limitations must be acknowledged. First, the primary model is murine bleomycin-induced fibrosis, which may not recapitulate all aspects of human idiopathic PF. Second, the reliance on genetic knockdown and overexpression, while mechanistically informative, may not fully predict the outcome of pharmacological interventions or naturally occurring disease. Additionally, the precise cell-type specificity of IGF2BP1 effects—beyond the macrophage compartment—warrants further clarification. Nonetheless, the demonstration of an IGF2BP1/THBS1/TLR4 axis provides a transferable concept for related fibrotic and inflammatory contexts, provided that species-specific and context-dependent regulatory mechanisms are considered.

Research Support Resources

For researchers seeking to replicate or extend these findings—particularly those investigating macrophage-mediated fibrosis or metabolic reprogramming—access to validated reagents for macrophage culture and differentiation is essential. Recombinant Mouse Macrophage Colony Stimulating Factor (M-CSF) without Tag (SKU PM2021) from APExBIO, produced in a HEK293 system and confirmed for bioactivity in mouse myelogenous leukemia lymphoblast proliferation assays, can provide a reliable foundation for macrophage survival, proliferation, and polarization workflows. Utilizing a species-specific, tag-free M-CSF ensures reproducibility in studies aiming to dissect the molecular mechanisms of macrophage activation and their contribution to fibrotic diseases.